Últimos Artículos de Endocrine Related Cancer
- Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center
- SDHA-related phaeochromocytoma and paraganglioma: review and clinical management
- Management of advanced high grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): comprehensive review of the current literature
- A pilot study of the immune microenvironment of GI neuroendocrine carcinoma
- Thyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes
- Distinct transcriptional and prognostic impacts of TERT promoter mutations C228T and C250T in papillary thyroid carcinoma
- Ectopic adrenocorticotropic hormone syndrome in patients with olfactory neuroblastoma
- ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs
- Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study
- AGEs induce MMP-9 promoter demethylation through the GADD45α-mediated BER pathway to promote breast cancer metastasis in patients with diabetes
- Genetic variants and down-regulation of CACNA1H in pheochromocytoma
- Insights on epidemiology, morbidity and mortality of Cushing’s disease in Northern Ireland
- Disease relapse in relation to lymph node sampling in lung carcinoid patients
- Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy
- The role of the tumor microenvironment in papillary thyroid microcarcinoma nodal metastasis
- Changes in categorization or nomenclature within neuroendocrine tumors
- Advancements and challenges in pheochromocytoma and paraganglioma research: a collection of insights
- EPAS1-related pheochromocytoma/paraganglioma
- Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs
- Importance of 3β-hydroxysteroid dehydrogenases and their clinical use in prostate cancer